Anna Sher, MD, PhD is a Director in the Quantitative Systems Pharmacology in the Clinical Pharmacology and Modeling and Simulation (CPMS) group at GSK. Anna received her MBBS (MD equivalent) from Imperial College London Medical School and a DPhil (PhD equivalent) in Computational Biology from the University of Oxford. Her doctorate work with Professors David Gavaghan and Denis Noble focused on modeling local calcium dynamics in heart muscle cells to gain insight into the role of the sodium-calcium exchanger in cardiomyocyte function. She continued postdoctoral research at the University of Oxford as part of the EU preDICT project to develop mathematical models of drug action in ventricular electrophysiology at the cellular level to assess pro-arrhythmic risk at the whole heart level. At Pfizer (2016-2022), Anna led cardiometabolic and hyperinsulinemia modeling efforts to support drug discovery and development programs at both preclinical and clinical stages. Recently Anna joined GSK to lead Quantitative Systems Pharmacology in non-Oncology therapeutic areas including Infectious disease, Neuroscience, NASH, Respiratory to support drug development at clinical stages.